Mallinckrodt Details Timeline And Financing For Spinning Off Generics Business
Executive Summary
Under plans announced last December, Mallinckrodt is to spin off its specialty generics and API business; at the recent Annual J.P. Morgan Healthcare Conference, management painted a timeline to completing the project and provided details on the business’ financing and growth prospects.
You may also be interested in...
Mallinckrodt Sets Out Four Priorities For 2019 And Foresees Specialty Generics Growth
Completing the planned spin-off of its specialty generics and API business into an independent publicly-traded company is one of four priorities that Mallinckrodt has set out for 2019. Despite expecting a “relatively negative” pricing environment this year, chief executive Mark Trudeau believes the Specialty Generics division will achieve growth.
Mallinckrodt Plans Spin-Off Of Specialty Generics Business
Disposing of its Specialty Generics business and becoming “brands-focused” has long been on Mallinckrodt’s agenda. The firm has now revealed plans to spin-off its generics division, while its remaining company will focus on innovative products.
Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.